Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Taniraleucel - Celularity

Drug Profile

Taniraleucel - Celularity

Alternative Names: CAR19-CYNK; Cord-blood-derived-natural-killer-cells-Celgene; CYNK 001; Placental-derived natural killer cell therapy - Celularity; PNK007

Latest Information Update: 17 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation
  • Developer Celgene Corporation; Celularity; Lung Biotechnology
  • Class Antineoplastics; Cell therapies; Haematopoietic stem cells therapies; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Glioma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute myeloid leukaemia
  • Phase I/II COVID 2019 infections; Glioblastoma; Multiple myeloma
  • No development reported Haematological malignancies; Solid tumours

Most Recent Events

  • 09 Dec 2023 Interim efficacy and adverse events data from the phase-I CYNK001AML01 trial in Acute myeloid leukaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 28 Sep 2023 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (IV)
  • 28 Sep 2023 No recent reports of development identified for preclinical development in Solid-tumours in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top